Epigenetics-focused Epizyme gains $90M upfront in deal with Celgene on targeted cancer therapies
This article was originally published in Scrip
Executive Summary
Epizyme, a US private firm founded in 2007 to focus on discovering new drugs based on epigenetic mechanisms, has formed a strategic partnership with oncology company Celgene that leverages the strengths of both companies. By working on joint programmes on a global basis, two firms hope to bring to market personalised therapies for patients with genetically defined cancers by inhibiting histone methytransferases (HMTs), an important epigenetic class.